The disease-modifying therapy (DMT) cladribine does not compromise the development of a specific humoral response in patients with multiple sclerosis (MS), according to a new study published in Multiple Sclerosis and Related Disorders. “For ocrelizumab and fingolimod, a significant [antibody] response can be achieved with further vaccinations,” the authors of the study wrote. These findings…
Higher doses of temelimab used together with rituximab have excellent safety and tolerability profile in patients with relapsing forms of multiple sclerosis (MS), according to the results of the phase 2 ProTEct-MS clinical trial. This means that the trial met its primary endpoint. “The fact that we here prove the feasibility and potential added benefit…
Researchers discovered that the gray matter lesions present in relapsing-remitting multiple sclerosis (MS) differ from those in neuromyelitis optica spectrum disorder (NMOSD) and published their results in the Journal of Neuroscience Research. MS and NMOSD are both characterized by the chronic inflammatory demyelination of the central nervous system. The link between these 2 diseases was…
Rituximab reinfusion after 9 months can suppress neuromyelitis optica spectrum disorder (NMOSD) relapses with an annualized relapse rate of 0.035 counts per person-years, according to results from a clinical trial of compassionate use of rituximab published in Multiple Sclerosis and Related Disorders. The trial called RIN-2 was the open-label extension of another multicenter, randomized, double-blind,…
A new randomized, blinded discontinuation trial of ocrelizumab in patients with early relapsing-remitting multiple sclerosis (MS) is expected to open soon. During the trial, an estimated 175 participants will be initiated with ocrelizumab at a dose of 300 mg twice separated by 2 weeks, the standard approved dose for the treatment. This will be followed…
Researchers discovered that following exposure to cerebrospinal fluid (CSF) from patients with progressive multiple sclerosis (MS), the differentiation of oligodendrocyte progenitor cells (OPCs) and the activation of their immune function in mice models were reduced, as published in Glia. MS is an autoimmune disease that attacks the central nervous system, causing neuroinflammation, demyelination, gliosis, and axonal…
The Fatigue Severity Impact Questionnaire-Relapsing Multiple Sclerosis (FSIQ-RMS) may be the most suitable patient-reported outcome (PRO) instrument for measuring progressive multiple sclerosis, according to a new study published in Neurology and Therapy. The researchers found that 80% (n=24) of the patients with progressive MS interviewed experienced both physical and mental fatigue and that the patients…
Transplantation of NG-01 cells offers neuroprotection for people with progressive multiple sclerosis (MS), according to results from a placebo-controlled phase 2 clinical trial. The announcement of the positive results was recently made by NeuroGenesis and Hadassah Medical Center. “This novel trial evaluated not only the clinical effects induced by the stem cell therapy, but also…
Adherence to a ketogenic diet for 6 months decreased body fat, inflammation, fatigue, depression, and disability in individuals with multiple sclerosis (MS), according to preliminary study findings revealed in a press release by the American Academy of Neurology. Researchers enrolled 65 individuals with relapsing-remitting MS into their study during which 83% of the participants fully…
Researchers discovered a rare case of neuromyelitis optica spectrum disorder (NMOSD) associated with cryptogenic organizing pneumonia (COP) in a young patient, as published in the European Journal of Case Reports in Internal Medicine. The case appears to be unique given that the only 2 prior reports of this association were in elderly patients. “This case…
